Neuroscience Antibodies & Assays Market by Product (Reagent (Media, Sera, Stain, Enzymes, Probe), Instruments), Technology (Immunoassay (Elisa), Molecular Diagnostics), Application (IVD) & End User (Research Institute, Hospital) - Global Forecast to 2023
“The global neuroscience antibodies and assays market projected to grow at a CAGR of 10.2%.”
The global neuroscience antibodies and assays market is expected to reach USD 4.18 billion by 2023 from USD 2.57 billion in 2018, at a CAGR of 10.2%. Growth in this market is driven by the rising incidence of neurological diseases, increasing investments in neuroscience research, and growth in the pharmaceutical and biotechnology industries. On the other hand, quality and cost concerns over the production of antibodies is the major factor restraining the growth of this market.
“Consumables are expected to grow at the highest CAGR during the forecast period.”
Based on product, the neuroscience antibodies and assays market is segmented into consumables and instruments. The consumables segment is expected to register the highest CAGR during the forecast period. The consistent usage of consumables and their frequent purchases, and rising government initiatives in the genomics and proteomics research sector are the major factors supporting the growth of the consumables segment.
“Pharmaceutical and biotechnology companies are expected to dominate the market during the forecast period.”
Based on end user, the neuroscience antibodies and assays market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and hospitals and diagnostic centers. The pharmaceutical and biotechnology companies segment is expected to account for the largest share of the neuroscience antibodies and assays market in 2018. The large share of this segment can be attributed to the high uptake of neuroscience antibodies in the drug discovery and development process and rising government initiatives in the genomics and proteomics research sectors.
“Asia to witness the highest growth during the forecast period.”
In 2018, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in the Asian market is attributed to factors such as growing research on proteomics and genomics, favorable funding scenario, and rising incidence of neurological diseases in the Asian region.
The primary interviews conducted for this report can be categorized as follows:
The report provides an overview of the neuroscience antibodies and assays market. It aims at estimating the market size and future growth potential of this market across different segments such as product, technology, application, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall neuroscience antibodies and assays market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers, restraints, and opportunities.
The global neuroscience antibodies and assays market is expected to reach USD 4.18 billion by 2023 from USD 2.57 billion in 2018, at a CAGR of 10.2%. Growth in this market is driven by the rising incidence of neurological diseases, increasing investments in neuroscience research, and growth in the pharmaceutical and biotechnology industries. On the other hand, quality and cost concerns over the production of antibodies is the major factor restraining the growth of this market.
“Consumables are expected to grow at the highest CAGR during the forecast period.”
Based on product, the neuroscience antibodies and assays market is segmented into consumables and instruments. The consumables segment is expected to register the highest CAGR during the forecast period. The consistent usage of consumables and their frequent purchases, and rising government initiatives in the genomics and proteomics research sector are the major factors supporting the growth of the consumables segment.
“Pharmaceutical and biotechnology companies are expected to dominate the market during the forecast period.”
Based on end user, the neuroscience antibodies and assays market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and hospitals and diagnostic centers. The pharmaceutical and biotechnology companies segment is expected to account for the largest share of the neuroscience antibodies and assays market in 2018. The large share of this segment can be attributed to the high uptake of neuroscience antibodies in the drug discovery and development process and rising government initiatives in the genomics and proteomics research sectors.
“Asia to witness the highest growth during the forecast period.”
In 2018, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in the Asian market is attributed to factors such as growing research on proteomics and genomics, favorable funding scenario, and rising incidence of neurological diseases in the Asian region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 30%; Tier 2 - 42%; Tier 3 - 28%.
- By Designation: C-level- 25%; D-level- 45%; Others- 30%.
- By Region: North America-38%; Europe-32%; Asia -24%; Rest of the World- 6%
- Thermo Fisher Scientific (US)
- Abcam (UK)
- Bio-Rad (US)
- Merck KGaA (Germany)
- BioLegend (US)
- Cell Signaling Technology (US)
- F. Hoffmann-La Roche (Switzerland)
- GenScript (China)
- Rockland Immunochemicals (US)
- Santa Cruz Biotechnology (US)
- Siemens (Germany)
- Tecan (Switzerland)
The report provides an overview of the neuroscience antibodies and assays market. It aims at estimating the market size and future growth potential of this market across different segments such as product, technology, application, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall neuroscience antibodies and assays market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers, restraints, and opportunities.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 SECONDARY DATA
2.1.1 SECONDARY SOURCE
2.2 PRIMARY DATA
2.2.1 KEY DATA FROM PRIMARY SOURCES
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 NEUROSCIENCE ANTIBODIES AND ASSAYS: MARKET OVERVIEW
4.2 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT (2018 VS. 2023)
4.3 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY (2018)
4.4 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER (2018–2023)
4.5 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising incidence of neurological diseases
5.2.1.2 Increasing investments in neuroscience research
5.2.1.3 Growth in the pharmaceutical and biotechnology industries
5.2.2 RESTRAINTS
5.2.2.1 Quality and cost concerns over the production of antibodies
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing demand for personalized medicine
5.2.3.2 Emerging markets to offer significant growth opportunities
5.2.3.3 Growing focus on biomarker discovery
6 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 REAGENTS
6.2.1.1 Media and sera
6.2.1.2 Stains and dyes
6.2.1.3 Fixatives
6.2.1.4 Buffers
6.2.1.5 Solvents
6.2.1.6 Enzymes, proteins, and peptides
6.2.1.7 Probes
6.2.1.8 Other reagents
6.2.2 ANTIBODIES
6.2.2.1 Primary antibodies
6.2.2.2 Secondary antibodies
6.2.3 ASSAY KITS
6.3 INSTRUMENTS
6.3.1 IMMUNOASSAY ANALYZERS
6.3.2 MICROPLATE READERS
6.3.3 OTHER INSTRUMENTS
7 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 IMMUNOASSAYS/IMMUNOCHEMISTRY
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
7.2.2 WESTERN BLOTTING
7.2.3 OTHER IMMUNOASSAY TECHNOLOGIES
7.3 MOLECULAR DIAGNOSTICS
7.4 CLINICAL CHEMISTRY
7.5 OTHER TECHNOLOGIES
8 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 DRUG DISCOVERY & DEVELOPMENT
8.3 RESEARCH
8.4 IN VITRO DIAGNOSTICS
9 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.3 ACADEMIC & RESEARCH INSTITUTES
9.4 HOSPITALS & DIAGNOSTICS CENTERS
10 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 REST OF EUROPE (ROE)
10.4 ASIA
10.5 REST OF THE WORLD (ROW)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS, 2017
11.3 COMPETITIVE SCENARIO
11.3.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2015–2018)
11.3.2 EXPANSIONS (2015–2018)
11.3.3 PRODUCT LAUNCHES (2015–2018)
11.3.4 ACQUISITIONS (2015–2018)
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 THERMO FISHER SCIENTIFIC
12.2 ABCAM
12.3 BIO-RAD
12.4 MERCK KGAA
12.5 CELL SIGNALING TECHNOLOGY
12.6 GENSCRIPT
12.7 ROCKLAND IMMUNOCHEMICALS
12.8 BIOLEGEND
12.9 SANTA CRUZ BIOTECHNOLOGY
12.10 TECAN
12.11 F. HOFFMANN-LA ROCHE
12.12 SIEMENS
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INSIGHTS FORM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.5 AVAILABLE CUSTOMIZATIONS
13.6 RELATED REPORTS
13.7 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 SECONDARY DATA
2.1.1 SECONDARY SOURCE
2.2 PRIMARY DATA
2.2.1 KEY DATA FROM PRIMARY SOURCES
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 NEUROSCIENCE ANTIBODIES AND ASSAYS: MARKET OVERVIEW
4.2 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT (2018 VS. 2023)
4.3 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY (2018)
4.4 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER (2018–2023)
4.5 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising incidence of neurological diseases
5.2.1.2 Increasing investments in neuroscience research
5.2.1.3 Growth in the pharmaceutical and biotechnology industries
5.2.2 RESTRAINTS
5.2.2.1 Quality and cost concerns over the production of antibodies
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing demand for personalized medicine
5.2.3.2 Emerging markets to offer significant growth opportunities
5.2.3.3 Growing focus on biomarker discovery
6 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 REAGENTS
6.2.1.1 Media and sera
6.2.1.2 Stains and dyes
6.2.1.3 Fixatives
6.2.1.4 Buffers
6.2.1.5 Solvents
6.2.1.6 Enzymes, proteins, and peptides
6.2.1.7 Probes
6.2.1.8 Other reagents
6.2.2 ANTIBODIES
6.2.2.1 Primary antibodies
6.2.2.2 Secondary antibodies
6.2.3 ASSAY KITS
6.3 INSTRUMENTS
6.3.1 IMMUNOASSAY ANALYZERS
6.3.2 MICROPLATE READERS
6.3.3 OTHER INSTRUMENTS
7 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 IMMUNOASSAYS/IMMUNOCHEMISTRY
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
7.2.2 WESTERN BLOTTING
7.2.3 OTHER IMMUNOASSAY TECHNOLOGIES
7.3 MOLECULAR DIAGNOSTICS
7.4 CLINICAL CHEMISTRY
7.5 OTHER TECHNOLOGIES
8 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 DRUG DISCOVERY & DEVELOPMENT
8.3 RESEARCH
8.4 IN VITRO DIAGNOSTICS
9 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.3 ACADEMIC & RESEARCH INSTITUTES
9.4 HOSPITALS & DIAGNOSTICS CENTERS
10 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 REST OF EUROPE (ROE)
10.4 ASIA
10.5 REST OF THE WORLD (ROW)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS, 2017
11.3 COMPETITIVE SCENARIO
11.3.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2015–2018)
11.3.2 EXPANSIONS (2015–2018)
11.3.3 PRODUCT LAUNCHES (2015–2018)
11.3.4 ACQUISITIONS (2015–2018)
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 THERMO FISHER SCIENTIFIC
12.2 ABCAM
12.3 BIO-RAD
12.4 MERCK KGAA
12.5 CELL SIGNALING TECHNOLOGY
12.6 GENSCRIPT
12.7 ROCKLAND IMMUNOCHEMICALS
12.8 BIOLEGEND
12.9 SANTA CRUZ BIOTECHNOLOGY
12.10 TECAN
12.11 F. HOFFMANN-LA ROCHE
12.12 SIEMENS
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INSIGHTS FORM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.5 AVAILABLE CUSTOMIZATIONS
13.6 RELATED REPORTS
13.7 AUTHOR DETAILS
LIST OF TABLES
Table 1 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 2 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY TYPE, 2016–2023 (USD MILLION)
Table 3 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY REGION, 2016–2023 (USD MILLION)
Table 4 REAGENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 5 REAGENTS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 6 MEDIA & SERA MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 7 STAINS AND DYES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 8 FIXATIVES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 9 BUFFERS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 10 SOLVENTS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 11 ENZYMES, PROTEINS, AND PEPTIDES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 12 PROBES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 13 OTHER REAGENTS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 14 ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 15 ANTIBODIES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 16 PRIMARY ANTIBODIES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 17 SECONDARY ANTIBODIES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 18 ASSAY KITS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 19 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY TYPE, 2016–2023 (USD MILLION)
Table 20 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY REGION, 2016–2023 (USD MILLION)
Table 21 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 22 MICROPLATE READERS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 23 OTHER INSTRUMENTS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 24 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 25 IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 26 IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 27 ELISA MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 28 WESTERN BLOTTING MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 29 OTHER IMMUNOASSAY TECHNOLOGIES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 30 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 31 CLINICAL CHEMISTRY MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 32 OTHER TECHNOLOGIES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 33 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 34 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2016–2023 (USD MILLION)
Table 35 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2016–2023 (USD MILLION)
Table 36 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR IN VITRO DIAGNOSTICS, BY REGION, 2016–2023 (USD MILLION)
Table 37 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 38 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2016–2023 (USD MILLION)
Table 39 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2016–2023 (USD MILLION)
Table 40 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2016–2023 (USD MILLION)
Table 41 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 42 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 43 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 44 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY TYPE, 2016–2023 (USD MILLION)
Table 45 NORTH AMERICA: REAGENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 46 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 47 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY TYPE, 2016–2023 (USD MILLION)
Table 48 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 49 NORTH AMERICA: IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 50 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 51 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 52 US: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 53 US: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 54 US: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 55 US: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 56 CANADA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 57 CANADA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 58 CANADA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 59 CANADA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 60 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 61 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 62 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY TYPE, 2016–2023 (USD MILLION)
Table 63 EUROPE: REAGENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 64 EUROPE: ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 65 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY TYPE, 2016–2023 (USD MILLION)
Table 66 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 67 EUROPE: IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 68 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 69 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 70 GERMANY: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 71 GERMANY: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 72 GERMANY: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 73 GERMANY: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 74 UK: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 75 UK: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 76 UK: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 77 UK: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 78 FRANCE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 79 FRANCE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 80 FRANCE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 81 FRANCE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 82 ROE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 83 ROE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 84 ROE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 85 ROE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 86 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 87 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY TYPE, 2016–2023 (USD MILLION)
Table 88 ASIA: REAGENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 89 ASIA: ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 90 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY TYPE, 2016–2023 (USD MILLION)
Table 91 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 92 ASIA: IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 93 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 94 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 95 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 96 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY TYPE, 2016–2023 (USD MILLION)
Table 97 ROW: REAGENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 98 ROW: ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 99 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY TYPE, 2016–2023 (USD MILLION)
Table 100 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 101 ROW: IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 102 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 103 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 1 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 2 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY TYPE, 2016–2023 (USD MILLION)
Table 3 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY REGION, 2016–2023 (USD MILLION)
Table 4 REAGENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 5 REAGENTS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 6 MEDIA & SERA MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 7 STAINS AND DYES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 8 FIXATIVES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 9 BUFFERS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 10 SOLVENTS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 11 ENZYMES, PROTEINS, AND PEPTIDES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 12 PROBES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 13 OTHER REAGENTS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 14 ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 15 ANTIBODIES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 16 PRIMARY ANTIBODIES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 17 SECONDARY ANTIBODIES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 18 ASSAY KITS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 19 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY TYPE, 2016–2023 (USD MILLION)
Table 20 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY REGION, 2016–2023 (USD MILLION)
Table 21 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 22 MICROPLATE READERS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 23 OTHER INSTRUMENTS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 24 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 25 IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 26 IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 27 ELISA MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 28 WESTERN BLOTTING MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 29 OTHER IMMUNOASSAY TECHNOLOGIES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 30 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 31 CLINICAL CHEMISTRY MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 32 OTHER TECHNOLOGIES MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 33 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 34 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2016–2023 (USD MILLION)
Table 35 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2016–2023 (USD MILLION)
Table 36 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR IN VITRO DIAGNOSTICS, BY REGION, 2016–2023 (USD MILLION)
Table 37 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 38 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2016–2023 (USD MILLION)
Table 39 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2016–2023 (USD MILLION)
Table 40 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2016–2023 (USD MILLION)
Table 41 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY REGION, 2016–2023 (USD MILLION)
Table 42 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 43 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 44 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY TYPE, 2016–2023 (USD MILLION)
Table 45 NORTH AMERICA: REAGENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 46 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 47 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY TYPE, 2016–2023 (USD MILLION)
Table 48 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 49 NORTH AMERICA: IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 50 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 51 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 52 US: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 53 US: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 54 US: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 55 US: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 56 CANADA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 57 CANADA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 58 CANADA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 59 CANADA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 60 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY COUNTRY, 2016–2023 (USD MILLION)
Table 61 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 62 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY TYPE, 2016–2023 (USD MILLION)
Table 63 EUROPE: REAGENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 64 EUROPE: ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 65 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY TYPE, 2016–2023 (USD MILLION)
Table 66 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 67 EUROPE: IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 68 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 69 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 70 GERMANY: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 71 GERMANY: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 72 GERMANY: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 73 GERMANY: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 74 UK: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 75 UK: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 76 UK: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 77 UK: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 78 FRANCE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 79 FRANCE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 80 FRANCE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 81 FRANCE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 82 ROE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 83 ROE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 84 ROE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 85 ROE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 86 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 87 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY TYPE, 2016–2023 (USD MILLION)
Table 88 ASIA: REAGENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 89 ASIA: ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 90 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY TYPE, 2016–2023 (USD MILLION)
Table 91 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 92 ASIA: IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 93 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 94 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
Table 95 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2016–2023 (USD MILLION)
Table 96 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR CONSUMABLES, BY TYPE, 2016–2023 (USD MILLION)
Table 97 ROW: REAGENTS MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 98 ROW: ANTIBODIES MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 99 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FOR INSTRUMENTS, BY TYPE, 2016–2023 (USD MILLION)
Table 100 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
Table 101 ROW: IMMUNOASSAYS/IMMUNOCHEMISTRY MARKET, BY TYPE, 2016–2023 (USD MILLION)
Table 102 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2016–2023 (USD MILLION)
Table 103 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2016–2023 (USD MILLION)
LIST OF FIGURES
Figure 1 RESEARCH DESIGN
Figure 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
Figure 4 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
Figure 5 DATA TRIANGULATION METHODOLOGY
Figure 6 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2018 VS. 2023 (USD BILLION)
Figure 7 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2018 VS. 2023 (USD BILLION)
Figure 8 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2018 VS. 2023 (USD BILLION)
Figure 9 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2018 VS. 2023 (USD BILLION)
Figure 10 GEOGRAPHICAL SNAPSHOT OF THE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET
Figure 11 INCREASING PREVALENCE OF NEUROLOGICAL DISEASES–KEY FACTOR PROPELLING THE MARKET FOR NEUROSCIENCE ANTIBODIES AND ASSAYS
Figure 12 CONSUMABLES WILL CONTINUE TO DOMINATE THE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET IN 2023
Figure 13 IMMUNOASSAYS/IMMUNOCHEMISTRY TO COMMAND THE LARGEST SHARE OF THE EUROPEAN NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET IN 2018
Figure 14 HOSPITALS AND DIAGNOSTICS CENTERS TO REGISTER THE HIGHEST GROWTH RATE BETWEEN 2018 & 2023
Figure 15 ASIA TO WITNESS THE HIGHEST GROWTH IN THE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET DURING THE FORECAST PERIOD (2018–2023)
Figure 16 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
Figure 17 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION)
Figure 18 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2018 VS. 2023 (USD MILLION)
Figure 19 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION)
Figure 20 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
Figure 21 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SNAPSHOT
Figure 22 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SNAPSHOT
Figure 23 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SNAPSHOT
Figure 24 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SNAPSHOT
Figure 25 KEY DEVELOPMENTS IN THE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BETWEEN 2015 TO 2018
Figure 26 MARKET EVOLUTION FRAMEWORK
Figure 27 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
Figure 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
Figure 29 ABCAM: COMPANY SNAPSHOT
Figure 30 BIO-RAD: COMPANY SNAPSHOT
Figure 31 MERCK KGAA: COMPANY SNAPSHOT
Figure 32 GENSCRIPT: COMPANY SNAPSHOT
Figure 33 TECAN: COMPANY SNAPSHOT
Figure 34 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
Figure 35 SIEMENS: COMPANY SNAPSHOT
Figure 1 RESEARCH DESIGN
Figure 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
Figure 4 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
Figure 5 DATA TRIANGULATION METHODOLOGY
Figure 6 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2018 VS. 2023 (USD BILLION)
Figure 7 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2018 VS. 2023 (USD BILLION)
Figure 8 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2018 VS. 2023 (USD BILLION)
Figure 9 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2018 VS. 2023 (USD BILLION)
Figure 10 GEOGRAPHICAL SNAPSHOT OF THE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET
Figure 11 INCREASING PREVALENCE OF NEUROLOGICAL DISEASES–KEY FACTOR PROPELLING THE MARKET FOR NEUROSCIENCE ANTIBODIES AND ASSAYS
Figure 12 CONSUMABLES WILL CONTINUE TO DOMINATE THE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET IN 2023
Figure 13 IMMUNOASSAYS/IMMUNOCHEMISTRY TO COMMAND THE LARGEST SHARE OF THE EUROPEAN NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET IN 2018
Figure 14 HOSPITALS AND DIAGNOSTICS CENTERS TO REGISTER THE HIGHEST GROWTH RATE BETWEEN 2018 & 2023
Figure 15 ASIA TO WITNESS THE HIGHEST GROWTH IN THE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET DURING THE FORECAST PERIOD (2018–2023)
Figure 16 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
Figure 17 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION)
Figure 18 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY TECHNOLOGY, 2018 VS. 2023 (USD MILLION)
Figure 19 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION)
Figure 20 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
Figure 21 NORTH AMERICA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SNAPSHOT
Figure 22 EUROPE: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SNAPSHOT
Figure 23 ASIA: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SNAPSHOT
Figure 24 ROW: NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SNAPSHOT
Figure 25 KEY DEVELOPMENTS IN THE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BETWEEN 2015 TO 2018
Figure 26 MARKET EVOLUTION FRAMEWORK
Figure 27 NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
Figure 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
Figure 29 ABCAM: COMPANY SNAPSHOT
Figure 30 BIO-RAD: COMPANY SNAPSHOT
Figure 31 MERCK KGAA: COMPANY SNAPSHOT
Figure 32 GENSCRIPT: COMPANY SNAPSHOT
Figure 33 TECAN: COMPANY SNAPSHOT
Figure 34 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
Figure 35 SIEMENS: COMPANY SNAPSHOT
